Ariosto Silva, PhD

Associations

• Metabolism and Physiology
• Pentecost Family Myeloma Research Center
• Cancer Biology & Evolution Program
• Cancer Imaging & Technology Center of Excellence
• Experimental Therapeutics Program
• Center of Excellence for Evolutionary Therapy

Education & Training

Graduate:

• Universidade Estadual Campinas- Unicamp, Brazil, PhD - Genetics and Molecular Biology

Fellowship:

• Moffitt Cancer Center -

Evolution of tumor invasiveness and adaptive tumor microenvironment particularly in multiple myeloma; cancer metabolism

• Tantawy M, Yang G, Algubelli RR, DeAvila G, Rubinstein SM, Cornell RF, Fradley MG, Siegel EM, Hampton OA, Silva AS, Lenihan D, Shain KH, Baz RC, Gong Y. Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma. Front Cardiovasc Med. 2023 Jun.10:1181806. Pubmedid: 37408649. Pmcid: PMC10319068.
• Morris BB, Smith JP, Zhang Q, Jiang Z, Hampton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, Dillon PM, Soliman HH, Stover DG, Colman H, Chakravarti A, Shain KH, Silva AS, Villano JL, Vogelbaum MA, Borges VF, Akerley WL, Gentzler RD, Hall RD, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA, Larner JM, Stukenberg PT, Jones DR, Mayo MW. Replicative Instability Drives Cancer Progression. Biomolecules. 2022 Oct.12(11). Pubmedid: 36358918. Pmcid: PMC9688014.
• Jiang Q, Sudalagunta P, Silva MC, Canevarolo RR, Zhao X, Ahmed KT, Alugubelli RR, DeAvila G, Tungesvik A, Perez L, Gatenby R, Gillies R, Baz R, Meads MB, Shain KH, Silva AS, Zhang W. CancerCellTracker: a brightfield time-lapse microscopy framework for cancer drug sensitivity estimation. Bioinformatics. 2022 Aug.38(16):4002-4010. Pubmedid: 35751591.
• Zhou L, Zhang Y, Meads MB, Dai Y, Ning Y, Hu X, Li L, Sharma K, Nkwocha J, Parker R, Bui D, McCarter J, Kramer L, Purcell C, Sudalagunta P, Renatino Canevarolo R, Coelho Siqueira Silva MD, DeAvila G, Alugubelli RR, Siqueira Silva A, Kmieciak M, Ferreira-Gonzalez A, Shain KH, Grant S. IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanisms. Blood Adv. 2021 Oct.5(19):3776-3788. Pubmedid: 34464977. Pmcid: PMC8679669.
• Hasipek M, Grabowski D, Guan Y, Alugubelli RR, Tiwari AD, Gu X, DeAvila GA, Silva AS, Meads MB, Parker Y, Lindner DJ, Saunthararajah Y, Shain KH, Maciejewski JP, Reu FJ, Phillips JG, Jha BK. Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma. Cancers (Basel). 2021 May.13(11). Pubmedid: 34071205. Pmcid: PMC8198550.
• Zhao X, Wang MY, Jiang H, Lwin T, Park PM, Gao J, Meads MB, Ren Y, Li T, Sun J, Fahmi NA, Singh S, Sehgal L, Wang X, Silva AS, Sotomayor EM, Shain KH, Cleveland JL, Wang M, Zhang W, Qi J, Shah BD, Tao J. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. Cell Rep. 2021 Mar.34(11):108870. Pubmedid: 33730585. Pmcid: PMC8057695.
• Koomen DC, Meads MB, Magaletti DM, Guingab-Cagmat JD, Oliveira PS, Fang B, Liu M, Welsh EA, Meke LE, Jiang Z, Hampton OA, Tungesvik A, De Avila G, Alugubelli RR, Nishihori T, Silva AS, Eschrich SA, Garrett TJ, Koomen JM, Shain KH. Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma. J Proteome Res. 2021 Jun.20(6):3134-3149. Pubmedid: 34014671.
• Mostofa A, Distler A, Meads MB, Sahakian E, Powers JJ, Achille A, Noyes D, Wright G, Fang B, Izumi V, Koomen J, Rampakrishnan R, Nguyen TP, De Avila G, Silva AS, Sudalagunta P, Canevarolo RR, Siqueira Silva MDC, Alugubelli RR, Dai HA, Kulkarni A, Dalton WS, Hampton OA, Welsh EA, Teer JK, Tungesvik A, Wright KL, Pinilla-Ibarz J, Sotomayor EM, Shain KH, Brayer J. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight. 2021 Dec.6(24). Pubmedid: 34793338. Pmcid: PMC8783683.
• Tichacek CJ, Tafreshi NK, Kil H, Engelman RW, Doligalski ML, Budzevich MM, Gage KL, McLaughlin ML, Wadas TJ, Silva A, Moros E, Morse DL. Biodistribution and Multicompartment Pharmacokinetic Analysis of a Targeted α Particle Therapy. Mol Pharm. 2020 Nov.17(11):4180-4188. Pubmedid: 32960613.
• Enderling H, Altrock PM, Andor N, Basanta D, Brown JS, Gatenby RA, Marusyk A, Rejniak KA, Silva A, Anderson ARA. High School Internship Program in Integrated Mathematical Oncology (HIP IMO): Five-Year Experience at Moffitt Cancer Center. Bull Math Biol. 2020 Jul.82(7):91. Pubmedid: 32648152.
• Sudalagunta P, Silva MC, Canevarolo RR, Alugubelli RR, DeAvila G, Tungesvik A, Perez L, Gatenby R, Gillies R, Baz R, Meads MB, Shain KH, Silva AS. A pharmacodynamic model of clinical synergy in multiple myeloma. EBioMedicine. 2020 Apr.54:102716. Pubmedid: 32268267. Pmcid: PMC7136599.
• Zhao X, Ren Y, Lawlor M, Shah BD, Park PMC, Lwin T, Wang X, Liu K, Wang M, Gao J, Li T, Xu M, Silva AS, Lee K, Zhang T, Koomen JM, Jiang H, Sudalagunta PR, Meads MB, Cheng F, Bi C, Fu K, Fan H, Dalton WS, Moscinski LC, Shain KH, Sotomayor EM, Wang GG, Gray NS, Cleveland JL, Qi J, Tao J. BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. Cancer Cell. 2019 May.35(5):752-766.e9. Pubmedid: 31085176. Pmcid: PMC6945775.
• Shah B, Zhao X, Silva AS, Shain KH, Tao J. Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All. Trends Cancer. 2018 Mar.4(3):197-206. Pubmedid: 29506670.
• Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J, Silva AS, Shah BD, Fang B, Li T, Koomen JM, Jiang H, Chavez JC, Pham L, Sudalagunta PR, Wan L, Wang X, Dalton WS, Moscinski LC, Shain KH, Vose J, Cleveland JL, Sotomayor EM, Fu K, Tao J. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J Clin Invest. 2018 Dec.128(12):5517-5530. Pubmedid: 30260324. Pmcid: PMC6264635.
• Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan Y, Pienta KJ, Anderson KS, Gatenby R, Swanton C, Posada D, Wu CI, Schiffman JD, Hwang ES, Polyak K, Anderson ARA, Brown JS, Greaves M, Shibata D. Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer. 2017 Oct.17(10):605-619. Pubmedid: 28912577. Pmcid: PMC5811185.
• Silva AS, Silva MC, Sudalagunta P, Distler AI, Jacobson T, Collins A, Nguyen T, Song J, Chen DT, Chen L, Cubitt CL, Baz R, Perez L, Rebatchouk D, Dalton W, Greene J, Gatenby RA, Gillies RJ, Sontag E, Meads MB, Shain K. An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma. Cancer Res. 2017 Jun.77(12):3336-3351. Pubmedid: 28400475. Pmcid: PMC7819642.
• Emmons MF, Anreddy N, Cuevas J, Steinberger K, Yang S, McLaughlin M, Silva A, Hazlehurst LA. MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma. Sci Rep. 2017 Jun.7(1):2685. Pubmedid: 28578393. Pmcid: PMC5457439.
• Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, Zhang L, Fu K, Bi C, Li J, Jiang H, Meads MB, Jacobson T, Silva M, Distler A, Darville L, Zhang L, Han Y, Rebatchouk D, Di Liberto M, Moscinski LC, Koomen JM, Dalton WS, Shain KH, Wang M, Sotomayor E, Tao J. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017 Apr.8:14920. Pubmedid: 28416797. Pmcid: PMC5399304.
• Enriquez-Navas PM, Kam Y, Das T, Hassan S, Silva A, Foroutan P, Ruiz E, Martinez G, Minton S, Gillies RJ, Gatenby RA. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci Transl Med. 2016 Feb.8(327):327ra24. Pubmedid: 26912903. Pmcid: PMC4962860.
• Silva A, Jacobson T, Meads M, Distler A, Shain K. An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells. J Vis Exp. 2015 Jul.(101):e53070. Pubmedid: 26274375. Pmcid: PMC4544963.
• Petersen PA, Silva AS, Gonçalves MB, Lapolli AL, Ferreira AM, Carbonari AW, Petrilli HM. Cd hyperfine interactions in DNA bases and DNA of mouse strains infected with Trypanosoma cruzi investigated by perturbed angular correlation spectroscopy and ab initio calculations. Biochemistry-Us. 2014 Jun.53(21):3446-3456. Pubmedid: 24801145.
• Khin ZP, Ribeiro ML, Jacobson T, Hazlehurst L, Perez L, Baz R, Shain K, Silva AS. A preclinical assay for chemosensitivity in multiple myeloma. Cancer Res. 2014 Jan.74(1):56-67. Pubmedid: 24310398. Pmcid: PMC3915502.
• Carvalho MG, Tsuneto LT, Moita Neto JM, Sousa LC, Sales Filho HL, Macêdo MB, Barroso JR, Pereira EM, Araújo AS, Silva AS, Monte SJ. HLA-A, HLA-B and HLA-DRB1 haplotype frequencies in Piauí's volunteer bone marrow donors enrolled at the Brazilian registry. Hum Immunol. 2013 Dec.74(12):1598-1602. Pubmedid: 23994585.
• Tafreshi NK, Silva A, Estrella VC, McCardle TW, Chen T, Jeune-Smith Y, Lloyd MC, Enkemann SA, Smalley KS, Sondak VK, Vagner J, Morse DL. In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma. Mol Pharm. 2013 Aug.10(8):3175-3185. Pubmedid: 23763620. Pmcid: PMC3785103.
• Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, Gatenby RA. Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res. 2012 Dec.72(24):6362-6370. Pubmedid: 23066036. Pmcid: PMC3525750.
• Ribeiro MdLC, Silva AS, Bailey KM, Kumar NB, Sellers TA, Gatenby RA, Arig IH, Gillies RJ. Buffer Therapy for Cancer. J Nutr Food Sci. 2012 Aug.2:6. Pubmedid: 24371544. Pmcid: PMC3872072.
• Lee HO, Silva AS, Concilio S, Li YS, Slifker M, Gatenby RA, Cheng JD. Evolution of tumor invasiveness: the adaptive tumor microenvironment landscape model. Cancer Res. 2011 Oct.71(20):6327-6337. Pubmedid: 21859828. Pmcid: PMC3197231.
• Silva AS, Gatenby RA. Adaptation to survival in germinal center is the initial step in onset of indolent stage of multiple myeloma. Mol Pharm. 2011 Dec.8(6):2012-2020. Pubmedid: 21958215. Pmcid: PMC3437606.
• Silva A, Anderson AR, Gatenby R. A multiscale model of the bone marrow and hematopoiesis. Math Biosci Eng. 2011 Apr.8(2):643-658. Pubmedid: 21631151. Pmcid: PMC3754791.
• Silva AS, Gatenby RA, Gillies RJ, Yunes JA. A quantitative theoretical model for the development of malignancy in ductal carcinoma in situ. J Theor Biol. 2010 Feb.262(4):601-613. Pubmedid: 19887072.
• Assumpção JG, Ganazza MA, de Araújo M, Silva AS, Scrideli CA, Brandalise SR, Yunes JA. Detection of clonal immunoglobulin and T-cell receptor gene rearrangements in childhood acute lymphoblastic leukemia using a low-cost PCR strategy. Pediatr Blood Cancer. 2010 Dec.55(7):1278-1286. Pubmedid: 20730889.
• Silva AS, Gatenby RA. A theoretical quantitative model for evolution of cancer chemotherapy resistance. Biol Direct. 2010 Apr.5:25. Pubmedid: 20406443. Pmcid: PMC2868834.
• Silva AS, Yunes JA, Gillies RJ, Gatenby RA. The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res. 2009 Mar.69(6):2677-2684. Pubmedid: 19276380. Pmcid: PMC3718046.
• Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res. 2009 Jun.69(11):4894-4903. Pubmedid: 19487300. Pmcid: PMC3728826.
• Silva AS, Yunes JA. Conservation of glycolytic oscillations in Saccharomyces cerevisiae and human pancreatic beta-cells: a study of metabolic robustness. Genet Mol Res. 2007 Apr.5(3):525-535. Pubmedid: 17117368.
• Rodrigues AS, Matos CB, Silva F, Fonseca I, Nogueira C, Santos J, Silva AS, Cabrita A. Long-term peritoneal dialysis experience in Portugal. Int J Artif Organs. 2006 Dec.29(12):1109-1116. Pubmedid: 17219350.

• Title: The effects of Selinexor on the MM and the immune effector cells in the context of T cell engagement
  Sponsor: Karyopharm Therapeutics, Inc.
  PI: Shain, K., CO-PI: Silva, A.
• Title: Ecology and Evolution of Breast Carcinogenesis
  Sponsor: Nat Institutes of Health
  PI (MPI): Silva, A.